Fulgent Genetics (FLGT)
Combines hereditary-cancer and pathology testing with a nanoencapsulated cancer-drug pipeline in clinical trials.
$21.31
vs last close−0.34 (−1.57%)
Something off on this page? Send us feedback.
Next report
Nov 6, 26
in 44 days
EPS estimate
−$0.65
Revenue estimate
$86.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Jul '26Nov '26
Reported$0.04$0.04$0.07$0.14$0.16−$0.36−$0.58Pending
Estimate−$0.31−$0.19−$0.23−$0.24$0.03−$0.35−$0.46−$0.65
Surprise+112.9%+121.1%+130.4%+158.3%+433.3%−3.4%−26.1%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Jul '26Nov '26
Reported$76.2M$73.5M$81.8M$84.1M$83.3M$71.1M$85.4MPending
Estimate$75.4M$77.0M$81.4M$85.4M$85.4M$68.1M$94.0M$86.3M
Surprise+1.1%−4.6%+0.5%−1.5%−2.4%+4.5%−9.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.34 | — | — |
| Sep 2028 | −$0.26 | — | — |
| Jun 2028 | −$0.29 | — | — |
| Mar 2028 | −$0.29 | — | — |
| Dec 2027 | −$0.34 | — | — |
| Sep 2027 | −$0.27 | — | — |
| Jun 2027 | −$0.27 | — | — |
| Mar 2027 | −$0.50 | — | — |
| Dec 2026 | −$0.69 | — | — |
| Nov 2026 | −$0.65 | — | — |
| Jul 2026 | −$0.46 | −$0.58 | −26.1% |
| May 2026 | −$0.35 | −$0.36 | −3.4% |
| Feb 2026 | $0.03 | $0.16 | +433.3% |
| Nov 2025 | −$0.24 | $0.14 | +158.3% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Sep 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.34 | — | — | $108.7M | — | — | — |
| Sep 2028 | −$0.26 | — | — | $103.4M | — | — | — |
| Jun 2028 | −$0.29 | — | — | $105.8M | — | — | — |
| Mar 2028 | −$0.29 | — | — | $102.2M | — | — | — |
| Dec 2027 | −$0.34 | — | — | $100.7M | — | — | — |
| Sep 2027 | −$0.27 | — | — | $95.8M | — | — | — |
| Jun 2027 | −$0.27 | — | — | $94.7M | — | — | — |
| Mar 2027 | −$0.50 | — | — | $91.5M | — | — | — |
| Dec 2026 | −$0.69 | — | — | $88.9M | — | — | — |
| Nov 6, 2026 | −$0.65 | — | — | $86.3M | — | — | — |
| Jul 30, 2026 | −$0.46 | −$0.58 | −26.1% | $94.0M | $85.4M | −9.2% | −18.1% |
| May 1, 2026 | −$0.35 | −$0.36 | −3.4% | $68.1M | $71.1M | +4.5% | −7.0% |
| Feb 27, 2026 | $0.03 | $0.16 | +433.3% | $85.4M | $83.3M | −2.4% | −38.1% |
| Nov 7, 2025 | −$0.24 | $0.14 | +158.3% | $85.4M | $84.1M | −1.5% | +18.2% |
| Aug 1, 2025 | |||||||
| May 2, 2025 | |||||||
| Feb 28, 2025 | |||||||
| Nov 8, 2024 | |||||||
| Aug 2, 2024 | |||||||
| May 3, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Nov 3, 2023 | |||||||
| Aug 4, 2023 | |||||||
| May 5, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 3, 2022 | |||||||
| Feb 23, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 4, 2020 | |||||||
| May 4, 2020 | |||||||
| Mar 10, 2020 | |||||||
| Nov 4, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 7, 2018 | |||||||
| Feb 28, 2018 | |||||||
| Nov 6, 2017 | |||||||
| Aug 7, 2017 | |||||||
| May 8, 2017 | |||||||
| Feb 27, 2017 | |||||||
| Nov 14, 2016 | |||||||
| Sep 29, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 |